Q4 2025 earnings call: revenue up 8%, AI-driven demand, and 2026 high single-digit growth outlook with margin guidance—read key takeaways.

The funding discussions highlight ongoing investor demand for new and unproven research labs looking to find novel approaches to AI that push the technology forward. Recursive’s goal is to develop ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

In other recent news, Exponent Inc. reported a strong third quarter for 2025, surpassing both earnings and revenue forecasts. The company achieved an earnings per share of $0.55, exceeding the ...

RXRX has reported updated data from its ELUCIDATE and TUPELO trials, but the stock has failed to mount a sustained rally. The ELUCIDATE update provides just an additional 10 patients of data treated ...

The University of Pennsylvania pushed back on the Trump administration’s subpoena to turn over lists of Jewish faculty, staff and students in a court filing on Jan. 20, calling the demand ...

At the outdoor entrance to Jerusalem’s International Convention Center — convenient for the artsy types arriving from Tel Aviv by train — roughly 200 protesters gathered on Dec. 30, with bullhorns and ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.32, marking a -3.36% move from the previous day. This change lagged the S&P 500's daily loss of 0.13%. On the other hand, ...